Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The most effective method to Pick the Right Material Organization: Fundamental Tips - 2Putin says Russian forces will seize capital of Zaporizhzhya
- 3Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
- 4Man who grabbed Ariana Grande at 'Wicked: For Good' premiere also rushed Katy Perry onstage this year. Who is he and why is he doing this?
- 5A photographer finds thousands of dinosaur footprints near Italian Winter Olympic venue
- Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- The Solution to Ecological Protection: Saving Nature for People in the future
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know)
- 6 Pet Sitting Administrations for Your Cherished Pets
- Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
- What loving-kindness meditation is and how to practice it in the new year
- 37 Things Just Individuals Experiencing childhood during the 80s Will Comprehend
- Well known SUVs With Low Energy Utilization In 2024 vote
